The Rebound-Risk Estimator is a feature the brand describes as an "educational estimate of post-medication rebound risk based on the habits and signals you log." The brand explicitly labels it as "behavioral nudges, not medical advice." Weight regain after GLP-1 discontinuation is a documented concern in published research - a 2025 systematic review and meta-analysis published in eClinicalMedicine confirmed that weight, HbA1c, and blood pressure consistently rebound after cessation
Semaglutide demonstrated 15-22% body weight reduction in STEP trials over 68 weeks, while tirzepatide achieved 22-26% reduction in ZEPBOUND studies
Many patients wonder whether Mounjaro (tirzepatide) is safe post-surgery, and the answer requires understanding both the drug's mechanism and your altered digestive physiology
D: Diameter Benign moles are generally smaller in diameter (less than 6mm), while melanomas may be larger
While the mechanistic data for how LDN and these specific peptides work is strong and growing, large-scale, double-blind clinical trials for their combined use in Hashimotos are still lacking
